Table of Contents

company-logo

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.

Protalix BioTherapeutics Dividend Announcement

• Protalix BioTherapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Protalix BioTherapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Protalix BioTherapeutics Dividend History

Protalix BioTherapeutics Dividend Yield

Protalix BioTherapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Protalix BioTherapeutics stock? Use our calculator to estimate your expected dividend yield:

Protalix BioTherapeutics Financial Ratios

P/E ratio-13.09
PEG ratio-4.81
P/B ratio3.88
ROE-30.89%
Payout ratio0.00%
Current ratio1.98
Quick ratio1.27
Cash Ratio1.13

Protalix BioTherapeutics Dividend FAQ

Does Protalix BioTherapeutics stock pay dividends?
Protalix BioTherapeutics does not currently pay dividends to its shareholders.
Has Protalix BioTherapeutics ever paid a dividend?
No, Protalix BioTherapeutics has no a history of paying dividends to its shareholders. Protalix BioTherapeutics is not known for its dividend payments.
Why doesn't Protalix BioTherapeutics pay dividends?
There are several potential reasons why Protalix BioTherapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Protalix BioTherapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Protalix BioTherapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Protalix BioTherapeutics a dividend aristocrat?
Protalix BioTherapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Protalix BioTherapeutics a dividend king?
Protalix BioTherapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Protalix BioTherapeutics a dividend stock?
No, Protalix BioTherapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Protalix BioTherapeutics stocks?
To buy Protalix BioTherapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Protalix BioTherapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.